MMSI Stock Forecast & Price Target

Merit Medical Systems is attractive because it combines durable mid-single-digit organic growth with expanding profitability, as management’s next long-term plan is expected to target 5%-7% organic revenue CAGR, 22.0%-24.0% adjusted operating margins by 2029, and roughly $700M of cumulative free cash flow, all while the company has already shown it can execute ahead of schedule by reaching its $400M cumulative FCF commitment a full year early. Its growth profile is supported by a balanced mix of a larger Foundational Products base and faster-growing Therapeutic Products, with the latter historically growing at an 11% CAGR versus 6% for Foundational Products, while gross margin expansion from 50.4% in 2023A to 54.0% in 2026E and disciplined operating expense control should continue to drive margin improvement. The outlook is further strengthened by a proven tuck-in acquisition strategy, including two recent acquisitions and 16 deals over the past 10 years totaling $1.2B, alongside a conservative balance sheet with 2.0x gross leverage and 0.8x net leverage, which gives the company flexibility to fund growth and potentially repurchase shares.

Merit Medical Systems is facing a more fragile fundamental backdrop than the bullish narrative suggests, because management itself has warned that the next long-range plan should not be expected to deliver the same pace of operating margin improvement seen in the prior two plan periods, while tariff and oil-price uncertainty still weighs on 2H26 guidance. Organic growth also appears less dependable than headline figures imply, with 1Q26 slowing to 2.7% from 6.6% in 4Q25, OEM sales falling 14% Y/Y, and the bear case explicitly assuming revenue growth of 5% or lower if recent acquisitions underperform and new product launches disappoint. Although Therapeutic sales rose 7% to $126M and Foundational sales increased 4% to $256M, China remains pressured by volume-based procurement pricing and management expects only flat sales there in 2026, limiting confidence that Merit's current momentum can translate into sustained earnings and margin expansion.